Drug Shortage Active
PRECEDEX is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PRECEDEX (dexmedetomidine hydrochloride) by Pfizer is 2 -adrenergic agonist with sedative properties. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 6d ago
PRECEDEX (dexmedetomidine hydrochloride) is a selective alpha-2 adrenergic agonist approved for sedation in intensive care and procedural settings. It works by activating alpha-2 receptors in the central nervous system to produce dose-dependent sedative effects, with selectivity maintained at lower to medium doses. The drug has been a cornerstone of ICU sedation protocols for over two decades.
PRECEDEX remains at peak commercial maturity as an established ICU standard, supporting stable brand and field teams focused on hospital/critical care channel management.
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10–300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
A Study to Learn About the Study Medicine - Precedex in Children From Japan.
Precedex Special Investigation (in Pediatric Patients)
Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Worked on PRECEDEX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRECEDEX positions you within Pfizer's stable, cash-generative critical care portfolio—ideal for building expertise in hospital formulary management, ICU protocols, and healthcare economics. As LOE approaches in 5-8 years, the role emphasizes defensive commercial strategy and stakeholder relationship management rather than launch-phase growth.